Drugs / DLI-X
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07254793 | Oct 2026 → Jun 2030 expected | acute lymphoblastic leukemia, acute undifferentiated leukemia, chronic myeloid leukemia, myelodysplastic syndrome | University of Arizona | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DLI-X | “Exercise-mobilized NK-enriched Donor Lymphocyte Infusions (DLI-X) to Prevent or Treat Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation” NCT07254793 ↗ |
| Modality | Cell therapy | “Exercise-mobilized NK-enriched Donor Lymphocyte Infusions (DLI-X)” NCT07254793 ↗ |
| Route | Other | “Pro-DLI-X will be given through the patient's central line” NCT07254793 ↗ |